Press Releases

Year 2014

December:

Day 09: Zydus launches world’s first biosimilar of Adalimumab

November:

Day 06: Zydus Cadila’s Net Profit up by 52% in Q2

September:

Day 16: Zydus receives tentative approval for Glipizide ER tablets
Day 15: Zydus and gilead enter into a generic licensing agreement to manufacture breakthrough treatment for hepatitis c

August:

Day 29: Zydus receives final approval for Telmisartan Tablets
Day 20: Zydus receives final approval for Acyclovir Tablets
Day 07: Zydus receives final approval for Potassium Citrate ER Tablets

July:

Day 30: Zydus Cadila Q1 Net profit up by 23%

June:

Day 09: Zydus announces data presentations on ZYDPLA1 “A once-weekly small molecule DPP-IV inhibitor for treating diabetes”, at the ENDO conference in Chicago, Illinois, USA.

May:

Day 29: Zydus explores newer treatment options with its breakthrough drug, LipaglynTM
Day 16: Zydus Cadila’s Net Profit zooms to Rs. 804 crore

April:

Day 15: Cadila Healthcare Limited Announces Settlement with Depomed on Gralise®

February:

Day 24: Zydus receives final approval for Clonidine Hcl Injection
Day 07: Zydus Cadila Net Profit up by 82% in Q3

January:

Day 09: Zydus receives final approval for Sirolimus Tablets with 180 days of marketing exclusivity

------------------------------------------------------------------------------------------------

Year 2013

December:

Day 11: Zydus Pharmaceuticals (USA) Inc agreement with Warner Chilcott Company LLC

October:

Day 31: Zydus Cadila registers 94% increase in Net Profit in Q2
Day 23: Zydus announces US FDA approval for initiating Phase I clinical trials of ‘ZYDPLA1’ – a novel next generation orally active, small molecule DPP-4 inhibitor to treat Type 2 Diabetes
Day 16: Zydus and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics

August:

Day 21: Zydus receives final approval for Lansoprazole DR Capsules

July:

Day 25: Zydus and IDRI sign agreement for the development of IDRI’s Vaccine Candidate for Visceral Leishmaniasis (Kala-Azar)

June:

Day 05: Zydus pioneers a breakthrough with LIPAGLYN, India’s first NCE to reach the market

May:

Day 30: Zydus Cadila’s Net Profit up by 54% in Q4
Day 16: Zydus scores with the Day 1 launch of Zolmitriptan in the US
Day 13: Zydus Wellness’ Net Profit up by 43.5% in FY ’13

March:

Day 30: Zydus Cadila receives tentative approval for Amlodipine Besylate and Benazepril Hydrochloride Capsules

February:

Day 27: Zydus Cadila receives tentative approval for Doxepin Hcl tablets
Day 25: Zydus receives final approval for Ranitidine Hcl injection
Day 14: Zydus receives final approval for Pioglitazone HCl tablets

------------------------------------------------------------------------------------------------

Year 2012

September:

Day 29: Zydus receives approval for Irbesartan Tablets

August:

Day 06: Zydus Cadila registers 30% growth in sales in Q1

July:

Day 27: Zydus Wellness’ Net Profit up by 59.6% in Q1
Day 19: Cadila Healthcare enters into a settlement and license agreement with Somaxon for Silenor®
Day 18: Zydus Urosciences launches Udenafil a next gen therapy for erectile dysfunction for the first time in India

February:

Day 07: Zydus Cadila Total Income up by 20% in Q3

------------------------------------------------------------------------------------------------

Year 2011

December:

Day 21: Zydus acquires 100% stake in Mumbai-based Biochem
Day 15: Zydus Cadila expands the Scientific Advisory Board at Zydus Research Centre

July:

Day 27: Zydus Cadila acquires German company, Bremer Pharma GmbH, from ICICI Venture, gains global footprint in animal healthcare business
Day 25: Zydus’ Baddi plant gets USFDA approval
Day 19: Zydus Cadila Q1 Net profit reaches Rs. 230 crore

June:

Day 17: Zydus’ US subsidiary enters into an asset purchase agreement in the US

May:

Day 06: Zydus Cadila’s Net Profit zooms by 41% in FY ’11
Day 05: Zydus Wellness’ Net Profit jumps by 31.4% in FY ’11

April:

Day 07: Zydus’ IND application of ZYGK1 for treating diabetes receives USFDA approval
Day 01: Zydus Cadila joins the billion dollar league

January:

Day 28: Bayer and Zydus join hands to set up a new pharmaceuticals Joint Venture in India
Day 18: Zydus Cadila’s Net Profit up by 25% in Q3
Day 17: Zydus Wellness’ Net Profit up by 36.6% in Q3

------------------------------------------------------------------------------------------------

Year 2010

October:

Day 19: Zydus Cadila registers 30% increase in Net Profit in Q2
Day 18: Zydus Wellness’ Net Profit up by 58% in Q2
Day 14: Zydus Cadila launches Pramipexole Tablets in the US market
Day 07: Zydus Cadila receives USFDA approval for Losartan Potassium tablets and Losartan Potassium + Hydrochlorothiazide tablets

September:

Day 29: Zydus Nycomed commissions the newly expanded API manufacturing facility at Navi Mumbai

July:

Day 16: Zydus Cadila Q1 Net profit up by 60%
Day 16: Zydus Wellness’ Net Profit up by 52.4% in Q1

June:

Day 29: Zydus Cadila launches Anastrazole Tablets in the US market on receiving USFDA approval
Day 21: Zydus’ novel orally administered GLP-1 agonist – ‘ZYOG1’ to treat Diabetes and Obesity enters Phase I clinical trial
Day 03: Vaxiflu-S – India’s first H1N1 vaccine is launched

May:

Day 12: Zydus Cadila to launch India’s 1st H1N1 vaccine
Day 11: Zydus Cadila and Abbott sign pact for commercialising branded generics in emerging markets

April:

Day 29: Zydus Cadila’s Net Profit zooms by 67% in FY ’10
Day 28: Zydus receives approval for Tamsulosin capsules

February:

Day 25: CHL announces Bonus Shares in the ratio of 1:2
Day 17: Mr. Pankaj R. Patel, CMD - Zydus Cadila, wins E&Y Entrepreneur of the Year - Healthcare and Life Sciences Award 2009

January:

Day 25: Zydus Cadila’s Net Profit up by 114% in Q3
Day 4: Zydus Cadila to start clinical trials of H1N1 vaccine

------------------------------------------------------------------------------------------------

Year 2009

December:

Day 31: Simayla becomes a 100% subsidiary of the Zydus Group

October:

Day 27: Zydus Cadila registers 39% increase in Net Profit in Q2

July:

Day 27: Zydus Cadila Q1 Net profit surges by 39%
Day 13: Zydus Cadila and Karo Bio’s research collaboration has generated promising lead compounds

June:

Day 4: Zydus files IND application with the DCGI for ‘ZYD1’ – a novel candidate to treat Diabetes and Obesity

May:

Day 5: Zydus receives approval for Mycophenolate Mofetil tablets and capsules

April:

Day 28: Zydus Cadila’s Total Income up by whopping 26% in FY 09
Day 2: Zydus files IND application with the USFDA for ‘ZYT1’ a novel candidate to treat dyslipidemia

March:

Day 31: Zydus receives final approval for Topiramate Tablets
Day 30: Zydus Cadila announces research collaboration to discover and develop new cardiovascular medicines
Day 4: Zydus Research Centre Receives AAALAC Accreditation

January:

Day 29: New Approvals strengthen Zydus’ US product basket
Day 27: Zydus Cadila’s Total Income up by 31% in Q3

---------------------------------------------------------------------------------------------------------

Year 2008

November:

Day 11: Zydus Cadila acquires Etna Biotech, a subsidiary of Crucell N.V.

October:

Day 22: Zydus Cadila registers 33% increase in Operating Net Profit in Q2
Day 20: Zydus receives approval for Risperidone Tablets
Day 16: Zydus files IND application for ‘ZYT1’ a novel candidate to treat dyslipidemia 
Day 14: Zydus Cadila becomes the 1st Indian Pharma company to receive WHO accreditation for Rabies vaccine

September:

Day 04: Zydus receives USFDA approval for Ramipril Capsules

August:

Day 12: Zydus and WHO to develop next-generation biologicals to fight rabies
Day 01: Zydus receives approval for Bromocriptine Mesylate Capsules

July:

Day 29: Zydus Cadila Q1 Net profit up by 21%
Day 04: Cadila Healthcare to restructure its consumer business and create a single listed entity

June:

Day 16: Zydus scores with first day launch of Venlafaxine Hydrochloride in the US
Day 09: Zydus acquires majority stake in Simayla Pharmaceuticals of South Africa

May:

Day 30: Zydus Cadila enters Spain, acquires Laboratorios Combix
Day 26: Zydus Cadila to market Benazepril in the US
Day 15: New Product Approvals for Zydus Cadila from USFDA

April:

Day 29: Zydus Cadila’s Net Sales up by whopping 27% in FY 08

March:

Day 11: Zydus and Nycomed expand scope of JV to create an API manufacturing hub for global supplies

February:

Day 15: Zydus Cadila firms up presence in Oncology segment with Nudoxa
Day 12: CRISIL reaffirms CADILA HEALTHCARE LIMITED’s ratings
Day 04: Zydus Cadila and Karo Bio of Sweden sign research agreement for a novel drug to treat inflammatory diseases

January:

Day 31: Zydus Cadila’s Income up by 22.7% in Q3
Day 24: Zydus Cadila and Prolong Pharmaceuticals ink pact for collaboration in Drug Discovery and Development

---------------------------------------------------------------------------------------------------------

Year 2007

October:

Day 26: Zydus Cadila registers 28% Income growth in Q2

September:

Day 25: Zydus Cadila receives USFDA approval for Hydroxychloroquine Sulfate Tablets
Day 06: Zydus Cadila receives USFDA approval for Carvedilol Tablets Launches product on the very same day

August:

Day 30: Zydus Cadila files its 5th IND ‘ZYH7’ - a novel drug candidate for treating dyslipidemia and metabolic disorders

July:

Day 31: Zydus Cadila Q1 Net profit up by 27%

June:

Day 25: Zydus Cadila acquires Brazilian company Nikkho
Day 06: Zydus Cadila receives tentative approval for Topiramate tablets

May:

Day 15: Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India
Day 14: Zydus Cadila buys out JV stake in Sarabhai Zydus Animal Health Ltd

April:

Day 26: Zydus Cadila’s Net Profit up by whopping 53% in FY 07
Day 20: Zydus receives tentative approval for Losartan Potassium tablets
Day 19: Zydus Cadila acquires Nippon Universal, strengthens its presence in Japan

March:

Day 17: New Approvals strengthen Zydus’ US product basket
Day 16: Zydus Cadila acquires Liva Healthcare, enters the 1500 cr. derma market
Day 12: Zydus Cadila receives USFDA approval for Paroxetine Tablets

February:

Day 05: Mr. P. R. Joshi, President Group HR, Zydus Cadila receives HR Leadership Award at the Asia Pacific HRM Congres

January:

Day 25: Zydus Research Centre to host International Symposium on Advances in Diabetes Therapy
Day 22: Zydus Cadila Q3 Net profit up by 66.4%


 
Copyright © Zyduscadila.com All rights reserved.